FOSTER CITY, Calif.--(BUSINESS WIRE)--Illumina® Ventures Labs, an early-stage company creation and investment engine with fully equipped genomics labs based in Foster City, CA and Cambridge, UK, is now operational and finalizing agreements with several startup companies. Illumina Ventures Labs is part of Illumina Ventures, the premier genomics and precision health venture firm supporting early-stage companies transforming healthcare and our world. With its extensive sequencing capabilities and state-of-the- ...

MENLO PARK, Calif., & TAMPA, Fla.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and BeniComp, a customized health plan provider, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test, to eligible patients initially through BeniComp Select members. This partnership underscores BeniComp’s commitment to proactive and preventive health management, enabling an even broader reach of their transformative ...

公司业绩 - Illumina公司在2023年第四季度取得了超出预期的业绩，主要是由于NovaSeq X仪器和耗材销售的增长[14] - 公司预计'24年的业绩将与'23年非常相似，受到市场不确定性的影响，预计客户在购买决策上会保持谨慎和限制[28] - Illumina对2024年营收和利润率的展望[60] 新产品和技术研发 - NovaSeq X是Illumina公司历史上最成功的产品推出，自推出以来已经收到了900个订单，并在2023年出货了352台仪器[16] - 公司已经推出了25B测序试剂盒和XLEAP-SBS化学试剂，以加强他们在全球的领导地位[23] - 公司在2023年底推出了25B流式细胞，同时改进了10B流式细胞的功能，这使得X耗材的销售在2023年底开始出现良好的增长势头，并预计这种势头将持续到2024年[108] 市场扩张和并购 - 公司最近收购了一家名为Partek的公司，这是一家专门从事多组学软件解决方案的公司，扩展了公司的能力并提升了软件组合的价值[25] - 公司宣布与Nashville Bioscience合作，加入了基因组发现联盟的三家新成员，包括BMS、GSK和Novo Nordisk[26] - 公司已经宣布将出售GRAIL，并计划在'24年第二季度结束前完成交易条款[43] 未来展望 - 公司将继续专注于客户第一，推动商业卓越，增长已安装基数，特别是NovaSeq X，并支持客户测序活动[30] - 公司致力于在运营上保持高度专注，包括在利润和生产力方面的提高，以及在其他领域降低成本[31] - Illumina对宏观经济形势的谨慎态度[62]

Illumina公司财务业绩 - Illumina公司宣布2023年第四季度和全年财务业绩[1] - Illumina公司鼓励投资者仔细考虑其GAAP结果以及补充的非GAAP信息[4] Illumina公司创新技术 - Illumina公司专注于创新，在DNA测序和基于阵列的技术方面成为全球领导者[6]

Shares of gene sequencing leader Illumina (ILMN 2.44%) rallied 36.6% in December, according to data from S&P Global Market Intelligence. Investors might not be quite so excited, as Illumina entered the month more than 80% below its all-time highs from 2021. But hopes for a bottoming and recovery surfaced in December, as Illumina received several positive analyst notes, and activist investor Carl Icahn made his next move in shaking up the company's board of directors. Is the company at the start of its recov ...

Illumina, Inc. (ILMN) recently entered into an agreement with Janssen Research & Development, LLC (Janssen) to develop its novel molecular residual disease (MRD) assay. The assay is a multi-cancer whole- genome sequencing (WGS) research solution that detects circulating tumor DNA (ctDNA) to better understand disease persistence or recurrence following treatment intervention. It is worth mentioning that MRD testing is increasingly being used in cancer as a predictive indication of disease recurrence followin ...

SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence o ...

SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss ...

AGD delivered ~86,000 whole genomes in 2023, including a unique diverse ancestry cohort Expanded pharma engagement enhances AGD's ability to develop multiomic datasets SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced three new memb ...

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: It is our view that SomaLogic’s considerable cash pos ...